Table 2.
Number of patients with adverse events following treatment
| Adverse Event | Grade | |||
|---|---|---|---|---|
| 1 | 2 | 3 | ||
| System Organ Class | Specific Term | |||
| Cardiac disorders | Tachycardia | 0 | 2 | 0 |
| Gastrointestinal disorders | Any AE - Maximum | 7 | 3 | 0 |
| Abdominal pain | 2 | 2 | 0 | |
| Constipation | 1 | 1 | 0 | |
| Diarrhea | 1 | 0 | 0 | |
| Nausea | 7 | 0 | 0 | |
| Vomiting | 5 | 1 | 0 | |
| General disorders and administration site conditions | Any AE - Maximum | 2 | 0 | 0 |
| Fatigue | 2 | 0 | 0 | |
| Edema peripheral | 1 | 0 | 0 | |
| Pyrexia | 1 | 0 | 0 | |
| Investigations | Any AE - Maximum | 3 | 0 | 1 |
| Alanine aminotransferase increased | 1 | 0 | 0 | |
| Aspartate aminotransferase increased | 1 | 0 | 0 | |
| Blood creatinine increased | 3 | 0 | 0 | |
| Hemoglobin decreased | 0 | 0 | 1 | |
| Metabolism and nutrition disorders | Any AE - Maximum | 4 | 2 | 0 |
| Decreased appetite | 3 | 0 | 0 | |
| Hypercalcemia | 0 | 1 | 0 | |
| Hyperkalemia | 0 | 1 | 0 | |
| Hypocalcaemia | 2 | 0 | 0 | |
| Hypomagnesaemia | 0 | 1 | 0 | |
| Musculoskeletal and connective tissue disorders | Any AE - Maximum | 1 | 1 | 0 |
| Flank pain | 0 | 1 | 0 | |
| Myalgia | 1 | 0 | 0 | |
| Nervous system disorders | Dizziness | 1 | 0 | 0 |
| Renal and urinary disorders | Hematuria | 1 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | Dyspnea | 1 | 0 | 0 |
| Vascular disorders | Hypotension | 0 | 1 | 0 |
| Injury, poisoning and procedural complications | Radiation skin injury | 0 | 1 | 0 |
| ANY AE - Maximum Grade Seen Total (percentage) | 6 (37.5) | 4 (25) | 1 (6) | |